(Q33623019)

28 July 2017

title

Early entecavir treatment for chronic hepatitis B with severe acute exacerbation (English)

1 reference

28 July 2017

1 reference

1 reference

1 reference

Wei-Lun Tsai

1

1 reference

28 July 2017

Po-Hung Chiang

2

1 reference

28 July 2017

Hoi-Hung Chan

3

1 reference

28 July 2017

Huey-Shyan Lin

4

1 reference

28 July 2017

Kwok-Hung Lai

5

1 reference

28 July 2017

Jin-Shiung Cheng

6

1 reference

28 July 2017

Wen-Chi Chen

7

1 reference

28 July 2017

Feng-Woei Tsay

8

1 reference

28 July 2017

Huay-Min Wang

9

1 reference

28 July 2017

Tzung-Jiun Tsai

10

1 reference

28 July 2017

Hsien-Chung Yu

11

1 reference

28 July 2017

Ping-I Hsu

12

1 reference

28 July 2017

language of work or name

English

0 references

publication date

13 January 2014

1 reference

Antimicrobial Agents and Chemotherapy

28 July 2017

published in

1 reference

28 July 2017

volume

58

1 reference

28 July 2017

issue

4

1 reference

28 July 2017

page(s)

1918-1921

1 reference

Entecavir versus lamivudine for patients with HBeAg-negative chronic hepatitis B.

28 July 2017

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023786

The role of lamivudine and predictors of mortality in severe flare-up of chronic hepatitis B with jaundice.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023786

Acute flares in chronic hepatitis B: the natural and unnatural history of an immunologically mediated liver disease

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023786

Lamivudine treatment in patients with severely decompensated cirrhosis due to replicating hepatitis B infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023786

Use of real-time PCR and fluorimetry to detect lamivudine resistance-associated mutations in hepatitis B virus.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023786

Acute exacerbation and superinfection in patients with chronic viral hepatitis.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023786

Evolving concepts of the clinical and serologic consequences of hepatitis B virus infection

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023786

Influential factors of prognosis in lamivudine treatment for patients with acute-on-chronic hepatitis B liver failure

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023786

Role of genotype and precore/basal core promoter mutations of hepatitis B virus in patients with chronic hepatitis B with acute exacerbation

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023786

A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023786

Lamivudine monotherapy for spontaneous severe acute exacerbation of chronic hepatitis B.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023786

Prognostic factors in severe exacerbation of chronic hepatitis B.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023786

The effect of lamivudine therapy in hepatic decompensation during acute exacerbation of chronic hepatitis B.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023786

Factors associated with hepatitis B virus DNA breakthrough in patients receiving prolonged lamivudine therapy.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023786

Lamivudine in the treatment of hepatitis B virus reactivation during cytotoxic chemotherapy

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023786

Acute exacerbations in Chinese patients with chronic hepatitis B virus (HBV) infection. Incidence, predisposing factors and etiology

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4023786

Lamivudine treatment for decompensated cirrhosis resulting from chronic hepatitis B

30 October 2018

1 reference

12 December 2020

Entecavir versus lamivudine in the treatment of chronic hepatitis B patients with hepatic decompensation

1 reference

12 December 2020

Reactivation of chronic type B hepatitis presenting as acute viral hepatitis

1 reference

12 December 2020

Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: a longitudinal study

1 reference

12 December 2020

Hepatitis B virus infection

1 reference

12 December 2020

Entecavir treatment in patients with severe acute exacerbation of chronic hepatitis B

1 reference

12 December 2020

Identifiers

DOI

10.1128/AAC.02400-13

1 reference

28 July 2017

1 reference

28 July 2017

1 reference